Monday, 18 July 2022, the Faculty of Public Health (FPH), Universitas Indonesia (UI), held an open doctoral promotion session on behalf of Santi Purna Sari. It was led by Prof. Dr. dr. Ratu Ayu Dewi Sartika, Apt. M.Sc., as Chairman of the Session, Prof. Budi Hidayat, S.K.M., M.P.P.M., Ph.D., as Promoter, Prof. Dr. drg. Madiati Nadjib, M.S., and Prof. Dr. dr. Pradana Soewondo, Sp.PD-KEMD as Co-Promoter. While the examiner team consisted of Prof. dr. Hasbullah Thabrany, M.P.H., Dr.PH .; Prof. Dra. Retnosari Andrajati, Apt., M.S., Ph.D .; and Dr. Dra. Agusdini Banun S., Apt., MARS. Santi defended her dissertation entitled “Effectiveness-Cost of Metformin+Dipeptidyl Peptidase-4 Combination Therapy Compared to Metformin+Sulfonylurea in Type 2 Diabetes Mellitus Patients”.
The trial was carried out boldly through the Zoom Meeting platform, which Prof. Dr. Arry Yanuar also witnessed, M.Si., Apt. as Dean of the Faculty of Pharmacy, University of Indonesia, and Dr. Rini Fatma Kartika, S.Ag., M.H., as Deputy Chancellor III of Muhammadiyah University Jakarta.
“In 2021, according to the International Diabetes Federation (IDF), Indonesia will be in fifth position with 19.47 million people with diabetes. With a population of 179.72 million, this means that the prevalence of diabetes in Indonesia is 10.6%,” said Santi, opening the summary of his dissertation.
This study aims to analyze the clinical effectiveness and cost-effectiveness of combination therapy with metformin+DPP4i and metformin+sulfonylureas in type 2 diabetes mellitus patients. be considered in making decisions on the management of type 2 diabetes mellitus in the hospital formulary.
The research was conducted through a research design divided into two stages: retrospective cohort including medical records and interviews with the EQ-5D-5L questionnaire and the Markov decision tree model. The research was conducted at DKI Jakarta Private Hospital from September 2019 to October 2020.
The results of Santi’s research showed that the effectiveness of the clinical therapy combination of metformin + DPP4i compared to metformin + sulfonylurea in the stated target of HbA1c <7% without hypoglycemia was 36.6%. Then, the difference in the total cost of metformin + DPP4i combination therapy compared to metformin + sulfonylurea therapy of IDR 2,340,768 and the use of metformin + DPP4i therapy can provide an additional 2.29 years of quality-adjusted life (QALY).
Santi suggested one of them to the Ministry of Health, BPJS, and other related institutions that could play a role in standard procedures and rules for using existing data in healthcare facilities. As for hospitals, it is recommended to increase access to research for the benefit of patients and hospitals.
Based on the results of his dissertation, Santi has successfully declared a graduate and became a Doctor in the Public Health Sciences (IKM). Santi is the 270th IKM doctoral graduate and the 349th doctoral graduate at FPH UI. (AHS)
